Akebia Therapeutics (AKBA) Fundamental Analysis: Revenue, Earnings & Valuation

3.42 / 10

Netural

Fundamental analysis rates AKBA at 3.4/10, indicating weak positioning. Cash‑MV and Asset‑MV are above average, but Revenue‑MV is negative and profit margins are low. YoY revenue growth is strong at 47%, yet income‑tax ratio drags performance, yielding a neutral outlook.

Analysis Checks(6/10)

Revenue-MV

Value-0.17

Score1/3

Weight26.95%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value47.46

Score3/3

Weight6.96%

1M Return1.54%

Inventory turnover ratio

Value2.48

Score2/3

Weight-5.03%

1M Return-1.21%

Gross profit margin (%)

Value83.29

Score0/3

Weight-26.16%

1M Return-7.24%

PB-ROE

Value0.05

Score0/3

Weight17.99%

1M Return3.23%

Income tax / Total profit (%)

Value-43.64

Score1/3

Weight-2.06%

1M Return-0.50%

Fixed assets turnover ratio

Value30.87

Score2/3

Weight-2.38%

1M Return-0.51%

Cost of sales ratio (%)

Value16.71

Score2/3

Weight-17.18%

1M Return-4.42%

Asset-MV

Value-0.55

Score2/3

Weight69.14%

1M Return12.22%

Cash-MV

Value0.66

Score2/3

Weight31.76%

1M Return5.94%

Is AKBA undervalued or overvalued?

AKBA scores 3.42/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -2.26% net margin, -69.66 P/E ratio, 11.42 P/B ratio, and 93.94% earnings growth, these metrics solidify its Netural investment rating.